Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

biohaven - BHVN

BHVN

Close Chg Chg %
45.17 1.35 2.99%

Open Market

46.52

+1.35 (2.99%)

Volume: 81.16K

Last Updated:

Nov 22, 2024, 11:45 AM EDT

Trade Now

Company Overview: biohaven - BHVN

BHVN Key Data

Open

$45.43

 Day Range

45.26 - 46.54

52 Week Range

26.81 - 62.21

 Market Cap

$4.73B

Shares Outstanding

100.95M

 Public Float

88.45M

Beta

4.12

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$9.35

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

728.01K

  

BHVN Performance

1 Week
 
 5.50%
 
1 Month
 
 -11.37%
 
3 Months
 
 12.22%
 
1 Year
 
 53.84%
 
5 Years
 
 -17.12%
 

BHVN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About biohaven - BHVN

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

BHVN At a Glance

Biohaven Ltd.
215 Church Street
New Haven, Connecticut 06510
Phone 1-203-404-0410 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -408,168,000.00
Sector Health Technology Employees 239
Fiscal Year-end 12 / 2024
View SEC Filings

BHVN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 8.112
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -6.229
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.011

BHVN Efficiency

Revenue/Employee N/A
Income Per Employee -1,707,815.90
Receivables Turnover N/A
Total Asset Turnover N/A

BHVN Liquidity

Current Ratio 7.983
Quick Ratio 7.983
Cash Ratio 6.913

BHVN Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -69.476
Return on Equity -84.442
Return on Total Capital -88.954
Return on Invested Capital -79.651

BHVN Capital Structure

Total Debt to Total Equity 7.215
Total Debt to Total Capital 6.729
Total Debt to Total Assets 6.016
Long-Term Debt to Equity 6.442
Long-Term Debt to Total Capital 6.008
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biohaven - BHVN

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
72.00K 1.39M 1.39M 3.37M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
72.00K 1.39M 1.39M 3.37M
Depreciation
72.00K 673.00K 1.36M 3.37M
Amortization of Intangibles
- - 720.00K 25.00K
-
COGS Growth
- +1,834.72% -0.50% +143.07%
Gross Income
(72.00K) (1.39M) (1.39M) (3.37M)
Gross Income Growth
- -1,834.72% +0.50% -143.07%
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
114.43M 217.51M 566.55M 432.68M
Research & Development
98.46M 181.49M 437.07M 373.28M
Other SG&A
15.97M 36.02M 129.47M 59.40M
SGA Growth
- +90.07% +160.47% -23.63%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(114.51M) (218.90M) (567.93M) (436.05M)
Non Operating Income/Expense
(4.16M) 6.47M (1.91M) 26.50M
Non-Operating Interest Income
- - - 17.73M
-
Equity in Earnings of Affiliates
- - (4.16M) 5.26M
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(118.67M) (212.43M) (569.84M) (409.55M)
Pretax Income Growth
- -79.01% -168.25% +28.13%
Pretax Margin
- - - -
-
Income Tax
- 1.37M 438.00K (1.38M)
Income Tax - Current - Domestic
- - 1.37M 438.00K
-
Income Tax - Current - Foreign
- - - (1.38M)
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - (4.16M) 5.26M
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(118.67M) (213.80M) (570.28M) (408.17M)
Minority Interest Expense
- - - -
-
Net Income
(118.67M) (213.80M) (570.28M) (408.17M)
Net Income Growth
- -80.16% -166.74% +28.43%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(118.67M) (213.80M) (570.28M) (408.17M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(118.67M) (213.80M) (570.28M) (408.17M)
EPS (Basic)
-1.8434 -3.321 -8.363 -5.7326
EPS (Basic) Growth
- -80.16% -151.82% +31.45%
Basic Shares Outstanding
64.38M 64.38M 68.19M 71.20M
EPS (Diluted)
-1.8434 -3.321 -8.363 -5.7326
EPS (Diluted) Growth
- -80.16% -151.82% +31.45%
Diluted Shares Outstanding
64.38M 64.38M 68.19M 71.20M
EBITDA
(114.43M) (217.51M) (566.55M) (432.68M)
EBITDA Growth
- -90.07% -160.47% +23.63%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 64.308
Number of Ratings 15 Current Quarters Estimate -1.607
FY Report Date 12 / 2024 Current Year's Estimate -8.846
Last Quarter’s Earnings -1.70 Median PE on CY Estimate N/A
Year Ago Earnings -5.73 Next Fiscal Year Estimate -6.311
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 8 15 14
Mean Estimate -1.61 -1.70 -8.85 -6.31
High Estimates -0.56 -1.49 -6.74 -5.29
Low Estimate -2.01 -1.88 -9.76 -7.51
Coefficient of Variance -22.92 -9.26 -8.59 -10.99

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 11
OVERWEIGHT 2 2 2
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Biohaven - BHVN

Date Name Shares Transaction Value
Jul 19, 2024 John Winston Childs Director 2,339,741 Open market or private purchase of non-derivative security Non-derivative transaction at $35.67 per share 83,458,561.47
Jun 20, 2024 Bruce D. Car Chief Scientific Officer 30,000 Open market or private purchase of non-derivative security Non-derivative transaction at $33.58 per share 1,007,400.00
May 15, 2024 Gregory H. Bailey Director 1,615,071 Open market or private purchase of non-derivative security Non-derivative transaction at $34.19 per share 55,219,277.49
May 3, 2024 Robert J. Hugin Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 3, 2024 Julia Paige Gregory Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 3, 2024 Michael Thomas Heffernan Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 3, 2024 Kishan C. Mehta Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 3, 2024 Irina Antonijevic Director 16,592 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 23, 2024 John Winston Childs Director 4,096,512 Open market or private purchase of non-derivative security Non-derivative transaction at $41 per share 167,956,992.00
Apr 23, 2024 John Winston Childs Director 2,254,841 Open market or private purchase of non-derivative security Non-derivative transaction at $41 per share 92,448,481.00
Apr 23, 2024 Vladimir Coric Chief Executive Officer; Director 1,788,417 Open market or private purchase of non-derivative security Non-derivative transaction at $41 per share 73,325,097.00
Apr 8, 2024 Vladimir Coric Chief Executive Officer; Director 840,890 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 8, 2024 Vladimir Coric Chief Executive Officer; Director 407,213 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Biohaven in the News